Laurus Labs Ltd
NSE:LAURUSLABS

Watchlist Manager
Laurus Labs Ltd Logo
Laurus Labs Ltd
NSE:LAURUSLABS
Watchlist
Price: 566.1 INR 1.23% Market Closed
Market Cap: 305.2B INR
Have any thoughts about
Laurus Labs Ltd?
Write Note

Laurus Labs Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Laurus Labs Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Laurus Labs Ltd
NSE:LAURUSLABS
Income from Continuing Operations
â‚ą1.3B
CAGR 3-Years
-50%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Income from Continuing Operations
â‚ą54.3B
CAGR 3-Years
40%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Income from Continuing Operations
â‚ą44.9B
CAGR 3-Years
20%
CAGR 5-Years
22%
CAGR 10-Years
14%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Income from Continuing Operations
â‚ą111.4B
CAGR 3-Years
21%
CAGR 5-Years
18%
CAGR 10-Years
5%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Income from Continuing Operations
â‚ą18B
CAGR 3-Years
12%
CAGR 5-Years
27%
CAGR 10-Years
8%
M
Mankind Pharma Ltd
NSE:MANKIND
Income from Continuing Operations
â‚ą19.4B
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Laurus Labs Ltd
Glance View

Market Cap
305.1B INR
Industry
Pharmaceuticals

Laurus Labs Ltd., an Indian pharmaceutical powerhouse, has etched its presence in the global pharma industry with a focus on delivering affordable and high-quality active pharmaceutical ingredients (APIs). Founded in 2005, the company's trajectory has been nothing short of remarkable, with an emphasis on research-driven production and sustainability. The Hyderabad-based conglomerate cultivates its core expertise within key therapeutic areas such as antiviral, cardiovascular, and oncology medications. By amalgamating scientific prowess with cutting-edge manufacturing facilities, Laurus Labs has positioned itself as a fundamental supplier in the fight against global ailments, providing APIs to some of the most critical generic pharmaceuticals worldwide. The company's commitment to health innovation is reflected in its robust portfolio of over 60 commercialized APIs, substantiating its pivotal role in the pharmaceutical supply chain. Adding another feather to its cap, Laurus Labs has ventured into the formulation business, manufacturing finished dosage forms that reach consumers directly. This vertical integration allows Laurus to capture a larger share of the pharmaceutical value chain, maximizing returns from its research and manufacturing capabilities. The company's foray into generic formulations has opened doors to new markets, particularly in challenging economies where cost-effective treatment is crucial. By leveraging its API expertise to produce effective, high-quality generic medications, Laurus Labs not only enhances its profitability but also adheres to its founding ethos of making healthcare accessible. With investments in research and development and a commitment to expanding its product line, Laurus Labs continues to strengthen its presence while nurturing partnerships globally, fueling its growth trajectory.

LAURUSLABS Intrinsic Value
393.12 INR
Overvaluation 31%
Intrinsic Value
Price

See Also

What is Laurus Labs Ltd's Income from Continuing Operations?
Income from Continuing Operations
1.3B INR

Based on the financial report for Sep 30, 2024, Laurus Labs Ltd's Income from Continuing Operations amounts to 1.3B INR.

What is Laurus Labs Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
0%

Over the last year, the Income from Continuing Operations growth was -65%. The average annual Income from Continuing Operations growth rates for Laurus Labs Ltd have been -50% over the past three years .

Back to Top